Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
PHASE2CompletedINTERVENTIONAL
Enrollment
60
Participants
Timeline
Start Date
September 30, 2006
Study Completion Date
March 31, 2007
Conditions
Chronic Small Plaque Psoriasis
Interventions
DRUG
RWJ-445380
All Listed Sponsors
lead
Alza Corporation, DE, USA
INDUSTRY
NCT00396422 - Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis | Biotech Hunter | Biotech Hunter